Details:
The funding will be used towards the development of Oligonucleotide-based Thearpies for the treatment of idiopathic pulmonary fibrosis (IPF), using SENISCA’s proprietary technology, harnessing RNA biology to rejuvenate aged senescent cells.
Lead Product(s): Oligonucleotide-based Thearpy
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undislcosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding April 20, 2023
Details:
MBS2320 is a first-in-class investigational drug which is currently in clinical development for the treatment of rheumatoid arthritis (RA) where it has demonstrated a unique profile, reducing inflammation and supporting the remodelling of damaged bone.
Lead Product(s): MBS2320
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MBS2320
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
C4XD signs licence agreement with AstraZeneca for the development and commercialisation of NRF2 Activator programme. NRF2 is an important natural regulator, controlling the expression of antioxidant genes, and it plays a key role in cellular defense against external insults.
Lead Product(s): C4X_6665
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C4X_6665
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $402.0 million Upfront Cash: $2.0 million
Deal Type: Agreement November 28, 2022
Details:
Under the terms of the agreement, AbbVie will pay DJS. DJS shareholders remain eligible for potential additional payments upon the achievement of certain development milestones related to the success of the DJS-002 program.
Lead Product(s): DJS-002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: DJS-002
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: $255.0 million
Deal Type: Acquisition October 20, 2022
Details:
NXP004 showed a dose-dependent reduction in the secretion of several key ECM components.These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.
Lead Product(s): NXP004
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NXP004
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).
Lead Product(s): RXC006
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $377.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2020
Details:
Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.
Lead Product(s): RXC007
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020